Retinoblastoma Treatment Market By Treatment Type (Systemic Chemotherapy, Intra-Arterial Chemotherapy, Intravitreal Chemotherapy, Focal Therapy, Radiation Therapy, Surgery); By Disease Presentation (Unilateral Intraocular Disease, Bilateral Intraocular Disease, Extraocular and Metastatic Disease, Recurrent or Refractory Disease); By End User (Specialist Children’s Hospitals, Ocular-Oncology Centers, General Hospitals, Cancer Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinoblastoma Treatment Market: Globe-Salvage Procedures Expand While Enucleation Remains Essential

The Global Retinoblastoma Treatment Market was valued at USD 1.93 billion in 2025 and is projected to reach USD 2.68 billion by 2032, growing at a CAGR of 4.79%, according to Strategic Market Research.

 

The Retinoblastoma Treatment Market combines hospital-administered chemotherapy, ophthalmic procedures, pediatric anesthesia, imaging, pathology and surgery. Newly diagnosed children and affected eyes are the most useful demand measures because one patient may undergo several chemotherapy cycles, examinations under anesthesia, focal treatments, intra-arterial infusions or intravitreal injections before tumor control is achieved. Enucleation remains necessary when an eye has little visual potential, carries high-risk features or does not respond safely to conservative treatment.

 

Public sources do not disclose dependable global treatment revenue, product-level drug sales or national procedure spending for this rare indication. Patient incidence, treatment mix, repeat procedure volume and specialist-center capacity provide a more reliable basis for assessing demand than retail prescription data. Standard chemotherapy medicines are largely generic, while hospitals capture a greater share of treatment expenditure through procedural delivery, anesthesia, imaging, surgery and multidisciplinary care.

 

A Rare Cancer with an Intensive Treatment Pathway

Retinoblastoma represents about 3% of childhood cancers and is usually diagnosed during the first few years of life. The disease affects approximately one in 15,000–20,000 live births, with the United States recording roughly 250–300 new diagnoses annually. Most children are diagnosed before age five, and the young age at presentation makes repeated anesthesia and family-supported treatment logistics part of routine care.

A Global Burden of Disease-based analysis estimated 6,274 incident cases, 57,333 prevalent cases, 2,762 deaths and 243,204 disability-adjusted life years in 2021. Prevalence includes survivors and children living with treatment consequences, so it should not be treated as the active therapy population. Delayed diagnosis, referral failure, treatment abandonment and limited access to ocular-oncology services further reduce the number of children who complete treatment.

Survival differs sharply by health-system capacity. Cure rates exceed 95% in many high-income countries, whereas survival in some low-income settings remains near 30%–40%. The Global Retinoblastoma Outcome Study reported estimated three-year survival only slightly above 50% in low-income countries. Mature markets therefore invest heavily in preserving the eye and useful vision, while lower-resource systems still face gaps in diagnosis, referral, treatment completion and access to specialist care.

 

Chemotherapy Accounts for the Largest Drug-Treated Population

The 4,043-patient Global Retinoblastoma Outcome Study recorded intravenous chemotherapy as the primary treatment for 1,937 patients, or 47.9%. Primary enucleation or exenteration was performed in 1,625 patients, representing 40.2% of the cohort. Treatment groups overlap because children initially treated with chemotherapy may later receive focal treatment, intra-arterial therapy or surgery. The data nevertheless confirm that hospital-administered chemotherapy and definitive surgery both account for substantial treatment activity.

Systemic treatment commonly combines carboplatin, vincristine and etoposide. Cyclophosphamide, topotecan, cisplatin and doxorubicin may be used in selected high-risk, recurrent, extraocular or metastatic cases. Chemotherapy can reduce tumor volume before laser, cryotherapy or plaque brachytherapy, and it may be required after enucleation when pathology identifies features associated with metastatic spread.

Generic availability limits pricing power for the medicines themselves. Hospitals generate more treatment expenditure through infusion services, pediatric oncology oversight, blood monitoring, anesthesia-supported examinations and subsequent ophthalmic procedures. Drug suppliers compete largely on reliable institutional supply and procurement terms rather than indication-specific product differentiation.

Pathology directly affects post-surgical chemotherapy use. In the Children’s Oncology Group ARET0332 study, central review found that 19% of 321 eligible children with enucleated unilateral disease had initially been assigned an incorrect pathological risk category. Children with defined high-risk features received six cycles of carboplatin, etoposide and vincristine every four weeks. Two-year event-free survival reached 98%, and overall survival reached 99%. Standardized pathology and risk assessment prevent unnecessary treatment in low-risk cases while directing adjuvant chemotherapy toward children most likely to benefit.

 

Intra-Arterial Chemotherapy Concentrates Spending in Specialist Centers

Intra-arterial chemotherapy delivers melphalan, carboplatin or topotecan through a microcatheter advanced toward the ophthalmic artery. Each treatment requires interventional radiology, angiographic imaging, pediatric anesthesia, catheter supplies and ocular-oncology oversight. The medicine represents only a small part of the total treatment cost.

Experienced multidisciplinary centers have reported ocular-salvage rates of approximately 70%–90% in selected advanced unilateral cases. Group D eyes and other eyes at high risk of enucleation account for much of the eligible population. Hospitals with established interventional teams can therefore retain patients who might otherwise undergo immediate surgery, although safe catheterization in infants and young children limits adoption outside major referral centers.

A randomized multicenter study summarized by the NCI compared four cycles of intra-arterial combination chemotherapy with six cycles of intravenous vincristine, carboplatin and etoposide in advanced unilateral disease. Two-year progression-free ocular salvage reached 53% with intra-arterial treatment and 27% with intravenous treatment. Overall ocular salvage was 71% and 51%, respectively. Better eye preservation in appropriately selected patients supports continued investment in catheter-based delivery, imaging and specialist training.

Safety requirements keep the procedure concentrated in experienced institutions. In a series of 196 patients receiving 682 intra-arterial infusions, ophthalmic vascular events occurred in 17% of treated eyes. Retinal artery occlusion, arterial stenosis, vitreous hemorrhage and retinal detachment can compromise vision or force a return to surgery. Hospitals adopting the procedure need reliable patient selection, dosing protocols, low-radiation imaging and teams experienced in pediatric catheterization.

 

Intravitreal Treatment Addresses Vitreous Seeding

Vitreous seeds are difficult to control because systemically administered drugs may not reach adequate concentrations within the vitreous. Intravitreal melphalan and topotecan place treatment directly into the eye and are commonly used alongside systemic or intra-arterial therapy.

A retrospective study cited by the NCI included 264 eyes in 250 children treated with intravitreal melphalan and reported complete remission in 68% of eyes. Extraocular spread associated with injection was uncommon, although retinal function may decline as cumulative exposure increases. Adoption therefore depends on safe injection technique, dose control and careful assessment of whether further eye preservation remains clinically appropriate.

The Phase II ARET2121 study is evaluating intravitreal melphalan during systemic carboplatin, vincristine and etoposide therapy for Group D disease with vitreous seeding. Successful early use could move intravitreal treatment from a predominantly salvage procedure into frontline care for selected patients. Hospitals would require additional ophthalmic drug preparation, anesthesia-supported examinations and protocol-based injection capacity.

 

Focal Therapy Adds Several Procedures to Each Salvage Course

Laser thermotherapy, cryotherapy and plaque brachytherapy commonly consolidate tumor control after chemotherapy. The number of procedures varies by tumor size, location, response and recurrence. Children may return every few weeks for examination and further treatment until no active tumor remains.

Laser treatment is generally used for selected posterior tumors, while cryotherapy is more suitable for accessible peripheral lesions. Plaque brachytherapy delivers localized radiation to persistent or recurrent tumors and is available mainly in specialist centers. Demand extends beyond capital equipment to applicators, maintenance, radioactive plaques, operating-room time and pediatric anesthesia.

A long-term cohort of 994 eyes in 554 patients treated with intravenous chemotherapy and additional intra-arterial chemotherapy or plaque treatment where required produced two-year tumor-control rates of 96% for Group A, 91% for Groups B and C, 71% for Group D and 32% for Group E eyes. Early-stage disease therefore produces a larger pool for repeated globe-salvage procedures, while low control in Group E disease preserves the role of definitive surgery.

 

Treatment Pathways and Patient Segments Shaping Market Demand

By treatment type, the market covers systemic, intra-arterial and intravitreal chemotherapy, focal treatment, radiation and surgery. Systemic chemotherapy reaches the largest drug-treated population. Intra-arterial and intravitreal therapies serve smaller patient groups but generate more expenditure per administration because they require anesthesia and specialist procedural delivery. Laser, cryotherapy and plaque brachytherapy add repeat treatment sessions, while enucleation remains the principal surgical segment.

By disease presentation, unilateral intraocular disease may be treated through targeted eye salvage or primary enucleation, depending on tumor size and visual potential. Bilateral disease creates greater demand for systemic treatment, repeated focal procedures, genetic testing and surveillance of both eyes. Extraocular, metastatic and recurrent disease represents a smaller but resource-intensive segment involving multi-agent chemotherapy, radiation and, in selected cases, stem-cell-supported treatment.

Specialist children’s hospitals and ocular-oncology centers dominate purchasing. Hospital pharmacies, pediatric cancer units, interventional neuroradiology departments, radiation centers, genetic laboratories and pathology services participate in the same treatment episode. North America and Western Europe have the strongest advanced globe-salvage infrastructure, while Asia carries the largest documented treatment volume and the widest variation in access.

 

Enucleation Remains Necessary in Advanced Disease

Enucleation is used when the eye is blind, painful, extensively filled by tumor or unlikely to retain useful vision. Surgery is also required when chemotherapy and focal treatment do not produce safe tumor control. The procedure includes pediatric anesthesia, removal of the eye and part of the optic nerve, pathology, placement of an orbital implant and later fitting of an ocular prosthesis.

Histopathology can lead directly to additional treatment. Optic nerve invasion, extensive choroidal involvement or other high-risk features may trigger adjuvant systemic chemotherapy. Surgical and pharmaceutical demand are therefore linked rather than separate.

NCI guidance discourages prolonged systemic treatment used only to postpone enucleation in Group E eyes. Pre-enucleation chemotherapy may obscure pathological evidence of extraocular spread and delay definitive disease control. Hospitals must balance eye preservation against survival risk rather than measure success only by avoiding surgery.

The Global Retinoblastoma Outcome Study reported primary enucleation or exenteration in 40.2% of patients, while approximately 65% underwent enucleation at some point during treatment. A considerable number of children therefore move from attempted salvage to surgery after progression, recurrence or inadequate response.

 

Radiation Is Reserved for Selected High-Risk Cases

External-beam radiation therapy is used less frequently because of facial growth abnormalities and the long-term risk of subsequent malignancies, especially in children with heritable RB1 alterations. Current use is concentrated in extraocular extension, orbital disease, metastatic involvement and selected tumors that continue to progress after other treatments.

NCI guidance lists external-beam doses of approximately 35–46 Gy. Young children may require sedation for each fraction, increasing anesthesia use and treatment complexity over several weeks. Proton and conformal radiation techniques can reduce exposure to nearby healthy tissue but remain available only in advanced centers.

A nonrandomized comparison in children with heritable disease reported a 10-year cumulative incidence of radiation-induced subsequent malignancies of 0% after proton therapy and 14% after photon therapy. Longer follow-up is needed, but reduced exposure to normal tissue gives proton therapy a role in selected children who still require radiation.

 

The United States Has Low Volume and High Treatment Intensity

Retinoblastoma affects boys and girls at similar rates and is diagnosed mainly before age five. Published estimates place U.S. annual incidence at approximately one case per 15,000–20,000 live births, resulting in roughly 250–300 new diagnoses each year. High survival shifts clinical spending toward preserving vision, minimizing long-term toxicity and monitoring children after treatment.

Around 60% of cases are unilateral, while bilateral disease accounts for the remainder. Estimates of heritable disease range from approximately 25%–30% under NCI classifications to around 40% in broader clinical descriptions. All bilateral cases and a smaller proportion of unilateral cases are presumed to carry a germline RB1 alteration.

Heritable disease extends care beyond initial tumor control. Children may require repeated examination of the second eye, brain imaging, testing of relatives and long-term screening for subsequent cancers. Genetic laboratories and surveillance services therefore participate in the treatment pathway even after chemotherapy or surgery has ended.

 

European Outcomes Remain Strong but Uneven

A 2024 EUROCARE-6 analysis included 3,262 patients from 81 cancer registries in 31 European countries. Incidence remained stable at approximately 4.0 cases per million children aged 0–14, and overall five-year survival reached 97.8%. Several countries reported 100% survival, while survival remained below 80% in Estonia and Bulgaria. Differences in diagnosis, referral and treatment delivery continue to affect outcomes despite Europe’s generally strong specialist infrastructure.

Approximately 70% of European cases were unilateral and 30% bilateral. Bilateral disease was diagnosed at a younger mean age than unilateral disease, increasing the period over which surveillance and second-cancer monitoring may be required.

The European cohort recorded 25 subsequent malignant neoplasms and calculated a standardized incidence ratio of 8.2. Hematological cancers and bone and soft-tissue sarcomas accounted for much of the increased risk. Genetic testing, survivorship clinics and long-term oncology surveillance therefore remain important even in countries where primary retinoblastoma survival approaches 100%.

 

Asia Carries the Largest Documented Treatment Volume

A prospective Asian study published in 2024 included 2,112 patients with 2,797 affected eyes treated at 96 centers in 33 countries. Intravenous chemotherapy was used in 1,450 eyes, or 52%, while 857 eyes, or 31%, underwent primary enucleation. South Asia contributed 1,021 patients, accounting for 48% of the cohort.

Advanced presentation restricts the use of straightforward eye-salvage treatment. The Asian cohort classified 41% of tumors as cT3 and 10% as cT4 at diagnosis. Late referral increases the need for enucleation, intensive chemotherapy and management of extraocular disease while lowering the probability of preserving useful vision.

Regional outcomes varied markedly. Estimated three-year mortality was 4% in East Asia and 22% in Southeast Asia. Drug supply alone cannot close that gap. Treatment completion depends on early recognition, affordable travel, specialist referral, pediatric anesthesia, shared-care networks and financial support for repeated visits.

 

VCN-01 Remains an Early Pipeline Asset

Routine pharmaceutical care depends largely on generic cytotoxic drugs, leaving few indication-specific commercial assets. Theriva Biologics is developing VCN-01, an intravitreally administered oncolytic adenovirus, for refractory retinoblastoma. The candidate has U.S. Orphan Drug and Rare Pediatric Disease designations and European orphan designation but remains investigational.

In May 2026, the company reported that two compassionate-use patients had received intravitreal VCN-01 with topotecan. Theriva was discussing a possible Phase II/III protocol and indicated that enrolment could begin in December 2026 if the protocol is submitted to and accepted by the FDA. Financing, regulatory alignment and stronger efficacy evidence remain necessary before the program can support a commercial forecast.

A treatment that controls refractory vitreous disease and prevents enucleation could achieve premium pricing despite the small eligible population. Adoption would depend on proving that VCN-01 improves eye salvage beyond intravitreal melphalan or topotecan without causing unacceptable ocular toxicity.

 

Treatment Growth Will Depend on Specialist Capacity

Intra-arterial chemotherapy, intravitreal injections, focal consolidation, anesthesia-supported examinations and genetic surveillance will account for most incremental treatment activity. Standard systemic chemotherapy will remain widely used but price-sensitive. Enucleation will continue to generate substantial procedural demand because advanced presentation and failed salvage cannot be eliminated through drug treatment alone.

Hospitals with integrated ophthalmology, pediatric oncology, pathology, anesthesia, interventional radiology and genetics services are best positioned to manage complex cases and adopt new protocols. North American and European centers will continue to prioritize visual outcomes and lower long-term toxicity. Asian and lower-income healthcare systems have greater potential to improve survival by reducing diagnostic delay, referral loss and treatment abandonment.

Retinoblastoma will remain a small market by patient count. Each child, however, can require several hospital encounters, multiple specialists and a combination of drugs, procedures and long-term surveillance, making institutional capability more important than broad pharmaceutical distribution.

 

Retinoblastoma Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.93 Billion
Revenue Forecast in 2032	USD 2.68 Billion
Overall Growth Rate	CAGR of 4.79% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Treatment Type, By Disease Presentation, By End User, By Geography
By Treatment Type	Systemic Chemotherapy, Intra-Arterial Chemotherapy, Intravitreal Chemotherapy, Focal Therapy, Radiation Therapy, Surgery
By Disease Presentation	Unilateral Intraocular Disease, Bilateral Intraocular Disease, Extraocular and Metastatic Disease, Recurrent or Refractory Disease
By End User	Specialist Children’s Hospitals, Ocular-Oncology Centers, General Hospitals, Cancer Treatment Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Expansion of globe-salvage procedures Rising use of intra-arterial and intravitreal chemotherapy Increasing specialist ocular-oncology capacity
Customization Option	Available upon request